While life science organizations tout “patient first,” in practice they think about the end customers too late in the development process. It’s understandable, because these later customers compete with the needs of more immediate customers, like: investors or C-suite leaders who are focused on derisking milestones, “potential business development partners who are looking for portfolio fit,” and key opinion leaders (KOLs) who are focused on their own scientific interests and are typically far removed from those who will be selecting and using the asset day to day. Feedback from these early customers shape development and launch decisions which, unfortunately, may be less helpful when it comes to planning for the everyday customer or end user. Even more, the company is consumed with meeting the needs of these near-term customers to keep development on track. That means any prelaunch tactics are being implemented without a distinct, long-term launch strategy in mind.
At Lime, we see clients across all company sizes missing the behavioral case for the asset or technology. For sure, safety, efficacy, and the clinical case establish the core evidence. And cost-effectiveness versus the current standard and impact on total cost outlay make the economic case for those paying for it. However, no matter the differentiated value, any new asset or technology often requires a corresponding change in beliefs and/or behaviors within the customer ecosystem in order for the launch to succeed. For example:
Follow the 4 Ps The sage wisdom found in the 4Ps of Marketing—Product, Place, Price, Promotion—can help teams think through customer implications coming out of the new asset or technology. After all, “launch” is simply marketing on steroids.
1 Rosenorn, P., Jaquet, P., & Bilodeau, TG. (2020, December 18). Biopharma launch trends: Lessons learned from L.E.K.’s launch monitor. Retrieved October 2, 2023 from https://www.lek.com/insights/ei/biopharma-launch-trends-lessons-learned-leks-launch-monitor